Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany

European Journal of Health Economics

Volumn 7, Issue 4, 2006, Pages 276-284

  Brennan, Alan ^a   Ara, Roberta ^a   Sterz, Raimund ^b   Matiba, Bernd ^b   Bergemann, Rito ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ABBOTT GMBH AND CO KG   (Germany)

^c Analytica International GmbH   (Germany)

Author keywords

Cost effectiveness analysis; Germany; Obesity; Sibutramine; Utility analysis

Indexed keywords

PLACEBO; SIBUTRAMINE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DIABETES MELLITUS; DIET; DRUG COST; FEMALE; GENERAL PRACTICE; GERMANY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH HAZARD; HEALTH SURVEY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; APPETITE DEPRESSANTS; CORONARY DISEASE; COST-BENEFIT ANALYSIS; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; DIET; FEMALE; GERMANY; HUMANS; LIFE STYLE; MALE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; WEIGHT LOSS;

EID: 33847249576     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0374-x     Document Type: Article

References (47)

1. Anonymous (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 8941: 253
2. Anderson KM, Wilson PW, Odell PM, Kannel WB (1991) An updated coronary risk profile. A statement for health professionals. Circulation 83: 356-362
3. Avenell A, Broom J, Brown TJ et al. (2004) Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 8(21): 111-182
4. Bergmann KE, Mensink GB (1999) Anthropometric data and obesity (in German). Gesundheitswesen 61: 115-120
5. Brazier J, Roberts J, Tsuchiya A, Busschbach J (2004) A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 13: 873-884
6. Brazier J, Usherwood T, Harper R, Thomas K (1998) Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 51: 1115-1128
7. Bundesministerium für Gesundheit und Soziale Sicherung und Bundesministerium für Bildung und Forschung. Body-Mass-Index - Prävalenzen. Bundes-Gesundheitssurvey 1998. Statistisches Bundesamt und Robert Koch-Institut . 2003. Electronic Citation
8. Büro für Informations Systeme (BIS) Christian de Haen (2004) Einheitlicher Bewertungsmassstab (EBM98). http://wwwe-bisde/ebm/Defaulthtm
9. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638
10. Esposito K, Pontillo A, Di Palo C et al. (2003) Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289: 1799-1804
11. Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288: 1723-1727
12. Fontaine KR, Cheskin LJ, Barofsky I (1996) Health-related quality of life in obese persons seeking treatment. J Fam Pract 43: 265-270
13. Fontaine KR, Redden DT, Wang C et al. (2003) Years of life lost due to obesity. JAMA 289: 187-193
14. Hauner H, Meier M, Wendland G, Lauterbach K (2004) Weight reduction by sibutramine in obese subjects in primary care medicine: the S.A.T.study group. Exp Clin Endocrinol Diabetes 112: 201-207
15. Hazenberg BP (2000) Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 94: 152-158
16. Heitmann BL, Garby L (1999) Patterns of long-term weight changes in overweight developing Danish men and women aged between 30 and 60 years. Int J Obes Relat Metab Disord 23: 1074-1078
17. Hubert HB, Feinleib M, McNamara PM, Castelli WP (1983) Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67: 968-977
18. James WP, Astrup A, Finer N et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356: 2119-2125
19. Jönsson B (2002) Revealing the cost of Ttpe II diabetes in Europe. Diabetologia 45(7): S5-12
20. Kenchaiah S, Evans JC, Levy D et al. (2002) Obesity and the risk of heart failure. N Engl J Med 347: 305-313
21. Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316: 736-741
22. Klever-Deichert G, Hinzpeter B, Hunsche E, Lauterbach KW (1999) Costs of coronary heart diseases over the remaining life time in coronary heart disease cases - an analysis of the current status of coronary heart disease cases in Germany from the social perspective (in German). Z Kardiol 88: 991-1000
23. Knowler WC, Barrett-Connor E, Fowler SE et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403
24. Kuntz KM, Tsevat J, Goldman L, Weinstein MC (1996) Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 94: 957-965
25. Kurscheid T, Lauterbach K (1998) The cost implications of obesity for health care and society. Int J Obes Relat Metab Disord 22 [Suppl 1]: S3-5
26. Narayan KM, Boyle JP, Thompson TJ et al. (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290: 1884-1890
27. Neter JE, Stam BE, Kok FJ et al. (2003) Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42: 878-884
28. Nisoli E, Carruba MO (2003) A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 26: 1027-1048
29. Ogden CL, Flegal KM, Carroll MD, Johnson CL (2002) Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 288: 1728-1732
30. Parker ED, Folsom AR (2003) Intentional weight loss and incidence of obesity-related cancers: the Iowa Women's Health Study. Int J Obes Relat Metab Disord 27: 1447-1452
31. Peeters A, Barendregt JJ, Willekens F et al. (2003) Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 138: 24-32
32. Pickin DM, McCabe CJ, Ramsay LE et al. (1999) Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 82: 325-332
33. Rexrode KM, Carey VJ, Hennekens CH et al. (1998) Abdominal adiposity and coronary heart disease in women. JAMA 280: 1843-1848
34. Rote Liste Service (2004) Rote Liste, Arzneimittelverzeichnis für Deutschland. http://wwwrote-listede
35. Sander B, Bergemann R (2003) Economic burden of obesity and its complications in Germany. Eur J Health Econ 4: 248-253
36. Scholze J (2002) Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters (in German). Dtsch Med Wochenschr 127: 606-610
37. Schwimmer JB, Burwinkle TM, Varni JW (2003) Health-related quality of life of severely obese children and adolescents. JAMA 289: 1813-1819
38. Seidell JC (2000) Obesity, insulin resistance and diabetes - a worldwide epidemic. Br J Nutr 83 [Suppl 1]: S5-8
39. Smith IG, Goulder MA (2001) Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 50: 505-512
40. Tuomilehto J, Lindstrom J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350
41. Vasan RS (2003) Cardiac function and obesity. Heart 89: 1127-1129
42. Warren E, Brennan A, Akehurst R (2004) Cost-effectiveness of sibutramine in the treatment of obesity. Med Decis Making 24: 9-19
43. Williamson DF, Thompson TJ, Thun M et al. (2000) Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23: 1499-1504
44. Winkelmayer WC, Weinstein MC, Mittleman MA et al. (2002) Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 22: 417-430
45. Wirth A (2004) Anhaltende Gewichtsreduktion nach Beendigung der Adipositasbehandlung mit Sibutramin. Dtsch Med Wochenschr 129: 1002-1005
46. Wirth A, Krause J (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286: 1331-1339
47. Zannad F, Gille B, Grentzinger A et al. (2002) Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 144: 508-515